Monte Rosa Therapeutics Unveils Preclinical Data on MRT‑8102 at AHA Scientific Sessions 2025

Biotech firm Monte Rosa Therapeutics, Inc. announced that it will present preclinical trial data for its novel compound MRT‑8102 — a first‑in‑class molecular glue degrader targeting the enzyme NEK7 — during the AHA Scientific Sessions 2025. The data suggest that MRT‑8102 effectively inhibits activation of the NLRP3 inflammasome, thereby reducing inflammatory cytokine release and pyroptotic cell death in models of cardiovascular and cardiometabolic disease such as pericarditis and atherosclerosis. The company highlights that MRT‑8102 is the only clinical‑stage degrader directed at NEK7. It achieved robust inhibition of NLRP3‑mediated pathways in vitro and in vivo, including superior performance in cholesterol crystal‑induced inflammation compared to an NLRP3 inhibitor in development. The poster presentation (poster #Sa4063) is scheduled for November 8 in New Orleans. Meanwhile, Monte Rosa is progressing its Phase 1 study in healthy volunteers and individuals at elevated cardiovascular‑disease risk, with initial human data expected in the first half of 2026. #MolecularGlue #CardiovascularInnovation #InflammationTherapies #MonteRosaTherapeutics #SlimScan #GrowthStocks #CANSLIM